Clinical Trial

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research is being done to test the safety and feasibility of an investigational DNA vaccine called pBI-11 and to find out what effects, if any, it has on women with persistent human papillomavirus 16 (HPV16+) and/or human papillomavirus (HPV18+) cervical infection. The DNA vaccine is designed to promote an immune response to treat disease caused by HPV types 16 and 18, viruses that can cause cervical cancer. The pBI-11 DNA vaccine or a placebo will be administered intramuscularly using the TriGridTM Delivery System.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-02
notable Primary completion moved earlier: 2029-03 -> 2028-11 2026-07-02
minor Completion moved earlier: 2030-03 -> 2029-05 2026-07-02
Trial Details
NCT Number NCT06210854
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: PapiVax Biotech, Inc., National Cancer Institute (NCI)
Conditions HPV Infection
Enrollment 48 participants
Start Date 2026-06-25
Primary Completion 2028-11 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-01